Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases

The Life Sciences Report | |

To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and

Two Companies Follow Unmet Needs to Biotech Profits: Echo He

The Life Sciences Report | |

Disease progression and drug resistance mean that very sick patients ultimately run out of options. In the case of orphan diseases, patients often run out of alternatives immediately after they

Catalyst Pharmaceutical Partners (CPRX) Plunges on Questionable Drug

Joel Anderson | |

Shares in small-cap biopharmaceutical company Catalyst Pharmaceutical Partners (CPRX) tumbled sharply Friday morning on heavy volume. Catalyst's stock opened down 21.5 percent, saw losses

Aegis Capital Is Changing the Way Investors Look at HealthCare Stocks

Equities Editors Desk | |

For the entire furor surrounding the upcoming implementation of “Obamacare” at the start of next year, few have been able to advance anything that resembles a comprehensive assessment

Is South Africa's Growing Economy a True Emerging Market?

Joel Anderson | |

South Africa made a major step into the world stage when it was added to the BRIC (Brazil, Russia, India, and China) group of countries to form BRICS. It was a sign that South Africa's economy has


Symbol Last Price Change % Change






Blockchain in Digital Identity - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Digital Identity